The study found that GDYO inhibits Mif-Ackr3 signaling in tumor cells and CAFs, reducing the number of regulatory T cells and tumor stem cells in TME, and ultimately inhibiting lymphoma growth (Figure S18B) [262]. The gene discussed is ACKR3; the disease is neoplasm.